Advertisement
- United States
- /
- Biotech
- /
- NasdaqCM:BIAF
bioAffinity Technologies Second Quarter 2025 Earnings: Misses Expectations
bioAffinity Technologies (NASDAQ:BIAF) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$1.27m (down 47% from 2Q 2024).
- Net loss: US$4.06m (loss widened by 92% from 2Q 2024).
- US$0.17 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
bioAffinity Technologies Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 70%.
Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 19% from a week ago.
Risk Analysis
You still need to take note of risks, for example - bioAffinity Technologies has 5 warning signs (and 4 which shouldn't be ignored) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:BIAF
bioAffinity Technologies
Engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Flawless balance sheet with slight risk.
Market Insights
Advertisement
Weekly Picks
LO
Lou_Basenese on Optimi Health ·
The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist
Fair Value:US$1155.3% undervalued
51 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
BL
BlackGoat on IREN ·
IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers
Fair Value:US$71.4849.2% undervalued
204 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
HE
HedgeY on Arm Holdings ·
The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?
Fair Value:US$43038.1% undervalued
9 followersusers have followed this narrative
1 commentusers have commented on this narrative
3 likesusers have liked this narrative
HI
Hidden_Rock_Capital on Fiserv ·
Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings
Fair Value:US$119.9956.4% undervalued
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
Recently Updated Narratives
EU
European_Hidden_Gem_Stocks on MINT Société anonyme ·
Mint SA: A French Micro-Cap Energy Retailer Worth Watching
Fair Value:€1153.1% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kaspertidemann on BAR DJUS ·
The Best Season Is Still Ahead
Fair Value:DKK 4.120.5% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CL
Clive_Thompson on Green Tea Group ·
One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Fair Value:HK$8.728.9% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
CU
CubanEros on Microsoft ·
A wonderful business at reasonable price.
Fair Value:US$419.917.3% undervalued
86 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
OS
oscargarcia on NVIDIA ·
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
Fair Value:US$28029.8% undervalued
195 followersusers have followed this narrative
9 commentsusers have commented on this narrative
15 likesusers have liked this narrative
BE
benjamin_lvieq on PayPal Holdings ·
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6513.7% undervalued
72 followersusers have followed this narrative
2 commentsusers have commented on this narrative
11 likesusers have liked this narrative
Trending Discussion
DE
derek_3wsdg on Teladoc Health ·
You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.
1
|0
